

## 4DMedical secures \$10m strategic investment from Pro Medicus

31 July 2025

### Highlights

- Pro Medicus (ASX:PME), a leading global medical imaging software company, has invested \$10m into 4DMedical
- This strategic investment will provide 4DMedical with the growth capital to accelerate its commercial pipeline for existing products while advancing CT:VQ™ towards regulatory clearance in the U.S.
- The investment is structured as a hybrid debt and equity loan that is non-dilutive if 4DMedical's share price is rangebound, while also creating upside alignment between Pro Medicus and 4DMedical's shareholders if the share price performs strongly over the two-year term
- The agreement also provides Pro Medicus with the option of distributing 4DMedical products on terms consistent with other distribution arrangements

**Melbourne, Australia, 31 July 2025** – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) a global leader in respiratory imaging technology, is pleased to announce it has entered into a secured facility agreement with Pro Medicus Limited (ASX:PME, “Pro Medicus”), a global leader in medical imaging software and solutions, to provide 4DMedical with \$10m (“Facility Agreement”). The Facility Agreement includes security as collateral and the material terms of the Facility Agreement are set out in Annexure 1.

This strategic investment will provide 4DMedical with growth capital to accelerate its commercial pipeline for existing products while advancing CT:VQ™ towards regulatory clearance in the United States.

### Pro Medicus

Pro Medicus is an ASX-listed global healthcare technology company specialising in medical imaging software and integrated informatics solutions. With over 30 years of experience, Pro Medicus has established itself as a trusted partner to major healthcare institutions worldwide, including Mayo Clinic, Johns Hopkins, and other leading hospitals and imaging centres across the U.S., Europe and Australia.

### Investor Webinar

4DMedical will hold an investor webinar tomorrow, Friday the 1 August at 9am AEST, where Dr Andreas Fouras will provide further information in relation to the Facility Agreement.

Please register in advance using the following links:

Webcast: <https://ccmediaframe.com/?id=w6CoVNTb>

Phone registration: <https://s1.c-conf.com/diamondpass/10049365-a7dhew.html>

After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.



#### 4DMedical MD/CEO and Founder Andreas Fouras said:

*Pro Medicus is a global leader in healthcare, and we are thrilled to receive their support at this pivotal moment in our journey. This strategic investment places us in a very strong position to take CT:VQ™ to market once it is cleared by the FDA.*

*4D stands at a very exciting moment, with rapid growth in sites and scans month on month against a backdrop of falling costs. Add to this the growing momentum in the Philips partnership, and the shortening timeline to expected FDA clearance of CT:VQ™, we are set for extremely strong performance over the coming months.*

—ENDS—

Authorised by the 4DMedical Board of Directors.

#### Contacts

##### Corporate

Investor Relations

[investor.relations@4dmedical.com](mailto:investor.relations@4dmedical.com)

##### Administration

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

##### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

#### About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)



## Annexure 1

Borrower	4DMedical Limited
Guarantor	4DMedical Limited and its Australian subsidiaries, and at the Lender's request, any other subsidiary of the Borrower.
Lender	Pro Medicus Limited
Commitment	AU\$10 million
Use of proceeds	Growth capital to accelerate 4DMedical's commercial pipeline for existing products while advancing CT:VQ™ towards regulatory clearance in the U.S.
Conditions to utilisation	Customary conditions precedent for a facility of this nature including: <ul style="list-style-type: none"><li>• execution of finance documents;</li><li>• insurance; and</li><li>• other key consents to the grant of security.</li></ul>
Interest	12.5% p.a.
Maturity	2 years
Security	Senior security customary for a facility of this nature being security over all assets of the Borrower and Guarantors, including specific security over certain assets.
Repayment	<p>At maturity, the Borrower will pay and/or issue the Lender with:</p> <p>(i) Cash equal to the higher of:</p> <p>a. \$12.5m; and</p> <p>b. \$10m x (4DX 10-day VWAP at maturity) / (4DX 10-day VWAP at execution), capped at \$20m.</p> <p>plus</p> <p>(ii) 4DX shares equal to: (\$10m x (4DX 10-day VWAP at maturity / 4DX 10-day VWAP at execution) – \$20m) / 4DX 10-day VWAP at maturity.</p> <p>If the Borrower is prevented by law or the ASX Listing Rules from issuing the relevant shares, the Borrower must cash settle the obligation to issue the shares by reference to the 10-day VWAP of 4DX shares at the relevant time.</p>
Representations & undertakings	Customary representations, undertakings and restrictions for a debt facility of this nature.
Events of default & review event	Customary events of default and review for a facility of this nature, including the Borrower's failure to obtain any relevant regulatory approvals.
Governing law	Victoria, Australia